Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.
- Author:
Renaud SABATIER
1
;
Véronique DIÉRAS
;
Xavier PIVOT
;
Etienne BRAIN
;
Henri ROCHÉ
;
Jean Marc EXTRA
;
Audrey MONNEUR
;
Magali PROVANSAL
;
Carole TARPIN
;
François BERTUCCI
;
Patrice VIENS
;
Christophe ZEMMOUR
;
Anthony GONÇALVES
Author Information
- Publication Type:Original Article
- Keywords: Metastatic breast cancer; Eribulin; Safety; Survival; Microtubule inhibition
- MeSH: Anthracyclines; Asthenia; Breast Neoplasms*; Breast*; Humans; Microtubules; Multivariate Analysis; Neutropenia; Prospective Studies*; Retrospective Studies; Taxoids
- From:Cancer Research and Treatment 2018;50(4):1226-1237
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Eribulin is approved for advanced breast cancers refractory to anthracyclines and taxanes. Efficacy according to sensitivity to previous therapies has been poorly explored. MATERIALS AND METHODS: Safety data were collected prospectively and we retrospectively collected efficacy data from the five French centres that participated in the Eribulin E7389-G000-398 expanded access program. Our main objectives were exploration of safety and analysis of eribulin efficacy (progression-free survival [PFS] and overall survival [OS]) according to sensitivity to the last microtubule-inhibiting agent administered. RESULTS: Median eribulin treatment duration was 3.3 months for the 250 patients included in this prospective single-arm study. Two hundreds and thirty-nine patients (95.6%) experienced an adverse event (AE) related to treatment including 129 (51.6%) with grade ≥ 3 AEs. The most frequently observed toxicities were cytopenias (59.6% of included patients), gastro-intestinal disorders (59.2%), and asthenia (56.4%). The most frequent grade 3-4 AE was neutropenia (37.2% with 4.8% febrile neutropenia). Median PFS and OS were 4.6 and 11.8 months, respectively. Patients classified as responders to the last microtubule-inhibiting therapy had a longer OS (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.51 to 0.94; p=0.017), and tended to display a better PFS (HR, 0.78; 95% CI, 0.58 to 1.04; p=0.086). OS improvement was still significant in multivariate analysis (adjusted HR, 0.53; 95% CI, 0.35 to 0.79; p=0.002). CONCLUSION: This work based on a prospective study suggests that identification of patients likely to be more sensitive to eribulin could be based on their previous response to microtubules inhibitors.
